Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial

Anne Derache, Collins C Iwuji, Kathy Baisley, Siva Danaviah, Anne-Geneviève Marcelin, Vincent Calvez, Tulio de Oliveira, François Dabis, Kholoud Porter, Deenan Pillay, Anne Derache, Collins C Iwuji, Kathy Baisley, Siva Danaviah, Anne-Geneviève Marcelin, Vincent Calvez, Tulio de Oliveira, François Dabis, Kholoud Porter, Deenan Pillay

Abstract

Background: Previous studies in human immunodeficiency virus (HIV)-positive individuals on thymidine analogue backbone antiretroviral therapy (ART) with either nevirapine or efavirenz have suggested poorer virological outcomes in the presence of pretreatment drug resistance (PDR). We assessed the impact of PDR on virological suppression (VS; <50 copies/mL) in individuals prescribed primarily tenofovir/emtricitabine/efavirenz in rural KwaZulu-Natal within a treatment-as-prevention trial.

Methods: Among 1557 HIV-positive individuals who reported no prior ART at study entry and provided plasma samples, 1328 individuals with entry viral load (VL) >1000 copies/mL had next-generation sequencing (NGS) of the HIV pol gene with MiSeq technology. Results were obtained for 1148 individuals, and the presence of PDR was assessed at 5% and 20% detection thresholds. Virological outcome was assessed using Cox regression in 837 of 920 ART initiators with at least 1 follow-up VL after ART initiation.

Results: PDR prevalence was 9.5% (109/1148) and 12.8% (147/1148) at 20% and 5% thresholds, respectively. After a median of 1.36 years (interquartile range, 0.91-2.13), mostly on fixed-dose combination tenofovir/emtricitabine/efavirenz, presence of both nonnucleoside reverse transcriptase inhibitor (NNRTI)/nucleoside reverse transcriptase inhibitor PDR vs no PDR was associated with longer time to VS (adjusted hazard ratio [aHR], 0.32; 95% confidence interval [CI], 0.12-0.86), while there was no difference between those with only NNRTI PDR vs no PDR (aHR, 1.05; 95% CI, 0.82-1.34) at the 5% threshold. Similar differences were observed for mutations detected at the 20% threshold, although without statistical significance.

Conclusions: NGS uncovered a high prevalence of PDR among participants enrolled in trial clinics in rural KwaZulu-Natal. Dual-class PDR to a mainly tenofovir/emtricitabine/efavirenz regimen was associated with poorer VS. However, there was no impact of NNRTI PDR alone.

Clinical trials tegistration: NCT01509508; South African National Clinical Trials Register: DOH-27-0512-3974.

Keywords: HIV; antiretroviral therapy; next-generation sequencing; pretreatment drug resistance; virological response.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Cohort flow chart. Abbreviations: ART, antiretroviral therapy; NGS, next-generation sequencing; TasP, Treatment-as-Prevention; VL, viral load.
Figure 2.
Figure 2.
Prevalence of any pretreatment drug resistance and nonnucleoside reverse transcriptase inhibitor resistance among 1148 participants with next-generation sequencing data detected at 5% and 20% detection thresholds. Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; PDR, pretreatment drug resistance.
Figure 3.
Figure 3.
Kaplan-Meier plot of the cumulative probability of virological suppression since antiretroviral therapy start; stratified by class of pretreatment drug resistance at the 20% (A) and 5% (B) detection thresholds. Abbreviations: ART, antiretroviral therapy; DRM, drug-resistance mutation; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PDR, pretreatment drug resistance; VL, viral load; VS, virological suppression.

References

    1. World Health Organization. Global AIDS Update 2016. Available at: . Accessed 06 October 2017.
    1. Lessells RJ, Mutevedzi PC, Iwuji CC, Newell ML. Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr 2014; 65:e17–24.
    1. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966–71.
    1. Boender TS, Hoenderboom BM, Sigaloff KC, et al. . Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin Infect Dis 2015; 61:1749–58.
    1. Hamers RL, Schuurman R, Sigaloff KC, et al. ; PharmAccess African Studies to Evaluate Resistance Investigators Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307–17.
    1. Chung MH, Beck IA, Dross S, et al. . Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. J Acquir Immune Defic Syndr 2014; 67:246–53.
    1. Hong SY, Jonas A, DeKlerk M, et al. . Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr 2015; 68:463–71.
    1. Kantor R, Smeaton L, Vardhanabhuti S, et al. ; AIDS Clinical Trials Group A5175 Study Team Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis 2015; 60:1541–9.
    1. Beck I, Levine M, Milne R, et al. . Impact of pre-treatment HIV-drug resistance on virologic outcome of first-line NNRTI-ART. CROI: Seattle: WA, 2017.
    1. Lee GQ, Bangsberg DR, Muzoora C, et al. . Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 2014; 30:896–906.
    1. Rusine J, Asiimwe-Kateera B, van de Wijgert J, et al. . Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One 2013; 8:e64345.
    1. Mzingwane ML, Tiemessen CT, Richter KL, Mayaphi SH, Hunt G, Bowyer SM. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?Virol J 2016; 13:170.
    1. Zoufaly A, Jochum J, Hammerl R, et al. . Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. J Antimicrob Chemother 2015; 70:922–5.
    1. Iwuji CC, Orne-Gliemann J, Larmarange J, et al. ; ANRS 12249 TasP Study Group. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV 2017; 5:e116–25.
    1. Massyn N, Peer N, English R, Padarath A, Barron P, Day C.. District health barometer 2015/2016. Westville, South Africa: Health Systems Trust, 2016.
    1. Iwuji CC, Orne-Gliemann J, Tanser F, et al. ; ANRS 12249 TasP Study Group Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013; 14:230.
    1. Iwuji CC, Orne-Gliemann J, Larmarange J, et al. ; ANRS 12249 TasP trial group Uptake of home-based HIV testing, linkage to care, and community attitudes about ART in rural KwaZulu-Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster-randomised trial. PLoS Med 2016; 13:e1002107.
    1. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. . Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36:1100–2.
    1. Gall A, Ferns B, Morris C, et al. . Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol 2012; 50:3838–44.
    1. Kearse M, Moir R, Wilson A, et al. . Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012; 28:1647–9.
    1. Lapointe HR, Dong W, Lee GQ, et al. . HIV drug resistance testing by high-multiplex “wide” sequencing on the MiSeq instrument. Antimicrob Agents Chemother 2015; 59:6824–33.
    1. Bennett DE, Camacho RJ, Otelea D, et al. . Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
    1. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28:964–74.
    1. Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012; 54:862–75.
    1. Wang LH, Begley J, St Claire RL III, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:1173–82.
    1. Yuen GJ, Lou Y, Bumgarner NF, et al. . Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48:176–82.
    1. Steegen K, Carmona S, Bronze M, et al. . Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first South African national survey. PLoS One 2016; 11:e0166305.
    1. Gupta RK, Gregson J, Parkin N, et al. . HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis 2018; 18:346–55.
    1. Iwuji C, Pillay S, Derache A, et al. ; Pillay D for the ANRS 12249 TasP Study Group Virologic suppression and emerging resistance on first-line antiretroviral therapy following universal test and treat: the ANRS 12249 cluster randomised trial. 9th IAS Conference on HIV Science Paris, France, 2017.
    1. Phillips AN, Stover J, Cambiano V, et al. . Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa. J Infect Dis 2017; 215:1362–5.
    1. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance. WHO: Geneva, Switzerland; 2016.
    1. UNAIDS. New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price. 2017. Available at: . Accessed 01 May 2018.
    1. Venter WF, Kaiser B, Pillay Y, et al. . Cutting the cost of South African antiretroviral therapy using newer, safer drugs. S Afr Med J 2016; 107:28–30.
    1. Walmsley S, Baumgarten A, Berenguer J, et al. . Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr 2015; 70:515–9.
    1. Walmsley SL, Antela A, Clumeck N, et al. ; SINGLE Investigators Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807–18.
    1. Cevik M, McGann H. Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital. Sex Transm Infect 2018; 94:420.
    1. Kandel CE, Walmsley SL. Dolutegravir–a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther 2015; 9:3547–55.
    1. World Health Organization. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Available at: . Accessed 05 Jun 2018.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する